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Abstract: Multidrug resistance in Pseudomonas aeruginosa is a noticeable and ongoing major obstacle
for inhibitor design. In P. aeruginosa, uridine diphosphate N-acetylglucosamine (UDP-GlcNAc)
acetyltransferase (PaLpxA) is an essential enzyme of lipid A biosynthesis and an attractive drug
target. PaLpxA is a homotrimer, and the binding pocket for its substrate, UDP-GlcNAc, is positioned
between the monomer A–monomer B interface. The uracil moiety binds at one monomer A,
the GlcNAc moiety binds at another monomer B, and a diphosphate form bonds with both monomers.
The catalytic residues are conserved and display a similar catalytic mechanism across orthologs,
but some distinctions exist between pocket sizes, residue differences, substrate positioning and
specificity. The analysis of diversified pockets, volumes, and ligand positions was determined
between orthologues that could aid in selective inhibitor development. Thenceforth, a complex-based
pharmacophore model was generated and subjected to virtual screening to identify compounds
with similar pharmacophoric properties. Docking and general Born-volume integral (GBVI) studies
demonstrated 10 best lead compounds with selective inhibition properties with essential residues in
the pocket. For biological access, these scaffolds complied with the Lipinski rule, no toxicity and drug
likeness properties, and were considered as lead compounds. Hence, these scaffolds could be helpful
for the development of potential selective PaLpxA inhibitors.
Keywords: PaLpxA; docking; pharmacophore; virtual screening; GBVI; ADME
1. Introduction
Multidrug-resistant (MDR) bacteria have been recently denoted ESKAPE 2242 (Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa and Enterobacter) pathogens [1]. P. aeruginosa is an opportunistic MDR pathogen,
with infection mostly occurring in humans during hospitalization. Since severe infection can be
life-threatening, researchers have attempted to design novel therapeutics [2]. Despite the fact that
current antimicrobials impede essential metabolic pathways in bacteria, they have become less effective
due to the emergence of drug resistance [3,4]. These obstacles can be overcome with the development
of novel therapeutics against alternative or drug-resistant targets. In P. aeruginosa, lipopolysaccharide
(LPS) is a vital part of the outer membrane, as in most Gram-negative bacteria, that protects it from
its environment and acts as a major virulence factor. LPS is a complex glycolipid mainly composed
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of three structurally different parts: (1) Lipid A, which anchors LPS to the outer membrane; (2) a
core oligosaccharide; and (3) O-antigen repeats, which are exhibited on the bacterial cell surface [5–7].
Lipid A biosynthesis is an evolutionarily conserved metabolic pathway among Gram-negative bacteria
requiring a series of nine enzymes, including LpxA, LpxC, LpxD, LpxH, LpxB, LpxK, WaaA, LpxL
and LpxM. Inhibition of the first six sequential enzymes inevitably kills the bacteria [8,9], while
no mammalian counterparts exist. Therefore, these enzymes become promising targets for the
development of potent antibacterial drugs.
A series of reactions are involved in lipid A biosynthesis. The initial three reactions are carried
out by LpxA, LpxC and LpxD. In the first reaction, the 3OH of UDP-GlcNAc are acylated with a
β-hydroxymyristoyl moiety from the acyl carrier protein (ACP) by LpxA, which is thermodynamically
unfavorable [10,11]. The subsequent reactions are thermodynamically favorable and catalyzed by
enzymes. LpxA is a functional homotrimer, with each monomer exhibiting a left-handed parallel
β-helix fold covered with 24 complete and six partial specific hexad repeats, with every turn in the
β-helix formed by a single hexapeptide [12]. LpxA has the ability to detect the specific length of the
acyl hydrocarbon through a hydrophobic cleft, either long or short. However, these acyl hydrocarbon
residues are implicated in the identification of a specific length of acyl chains, a so-called hydrocarbon
ruler, which is different across species [13]. Recently, the crystal structure of PaLpxA has been resolved
with substrate and product, providing definite enzyme catalysis and substrate-binding evidence
that aid in the development of new classes of antibacterial agents [14]. PaLpxA complexed with
substrate (UDP-GlcNAc) and product revealed UDP-GlcNAc to be bound at the catalytic cleft of the
protein–protein interface. UDP interacts with the UDP pocket residues of Ile148, Phe166, Asn194,
Glu196, Arg200 and Arg201 of one monomer, whereas GlcNAc interacts with the GlcNAc pocket
residues of Asp70, Leu71, His121, His140, His156 and Gln157 from another monomer connected
by a diphosphate bridge [14,15]. Mutagenesis studies documented His121 at the GlcNAc pocket
participates in catalysis to deprotonate the UDP-GlcNAc and facilitate a nucleophilic environment
for the attachment of the acyl moiety [13]. So far, some peptide and small molecule inhibitors have
been reported to thwart LpxA function by competing with acyl-ACP and UDP-GlcNAc in various
orthologues [16]. Peptide920 is a peptide inhibitor 15 amino acids long competing for acyl chain binding
site with inhibitory concentration of Ki = 50 nM against Escherichia coli LpxA [17]. RJPXD33 is an
antimicrobial peptide which showed dual inhibition for LpxA and LpxD by competing with acyl-ACP
substrate [18]. Recently, peptideCR20 was reported with IC50 of ≈50 nM against E. coli LpxA [19].
Even though these peptides exert potential activity, they confer poor bioavailability and susceptibility.
Alternatively, small molecules with substrate-mimicking properties have been discovered for Moraxella
catarrhalis [20]. However, specific inhibitors have not been investigated for PaLpxA and must be
explored for persuasive inhibitors to thwart the P. aeruginosa infections. In this scenario, our efforts are
utilized to develop effective PaLpxA inhibitors using predictive in silico experiments and to manage
the clinical settings for effective management of infectious diseases.
2. Materials and Methods
2.1. Binding Pocket and Volumetric Analysis
LpxA crystal structures—without water, cofactors and cocrystal ligands—of P. aeruginosa (PDB
ID: 5DEP, 5DEM, 5DG3), A. baumannii (PDB ID:4E6Q) [21], E. coli (PDB ID:2JF3), Helicobacter pylori
(PDB ID: 1J2Z) [22], Leptospira interrogans (PDB ID: 3HSQ) [23] and Burkholderia thailandensis (PDB
ID:4EQY) [24] were retrieved from the Protein Data Bank (PDB). All crystal structures were subjected
to root mean square deviation (RMSD) analysis, binding cavity volumetric and shape analysis carried
out using the Site Finder module of the molecular operating environment (MOE) program [25].
Site Finder calculates possible active sites in the receptor using 3D atomic coordinates. The site
finder parameters were set as follows: Probe radius 1 was 1.4 Å, probe radius 2 was 1.8 Å, isolated
donors/acceptors were 3, connection distance was 2.5 Å, minimum site size was 3 Å, and radius was
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2 Å. This module uses the geometric category of methods and is primarily based upon the alpha
spheres, which are generalized convex hulls [26]. The tight atomic packing regions were identified
and filtered out for being over-exposed to solvent. Then, the site was classified as either hydrophobic
or hydrophilic. The collected alpha spheres were clustered by using a double-linkage algorithm to
produce ligand-binding sites and rank the sites according to their propensity for ligand binding (PLB)
based on the amino acid composition of the pocket [27].
2.2. Ligand Preparation
The NCI drug database contains 265,242 heterogenous compounds, including 3D atomic
coordinates, molecular formulas, molecular weights, and IUPAC structure identifiers, such as standard
InChI and standard InChIKey, all of which were downloaded from the National Cancer Institute
(http://cactus.nci.nih.gov/download/nci). This dataset was launched into MOE through database viewer
and primarily subjected to wash to correct errors in the structures, such as single bonds, protonation,
disordered bond lengths, tautomers, ionization states, and explicit counter ions. All the compounds
were converted to 3D conformations, hydrogen and atomic partial charges were applied, and energy
minimization was performed with an MMFF94x force field for small molecules. The refined dataset
was utilized for further experiments.
2.3. Pharmacophore Modeling and Virtual Screening
The complex-based pharmacophore technique was used to improve the drug development process.
A pharmacophore is the combined steric and electronic features of the ligand that are necessary to ensure
the optimal supramolecular interactions with a specific biological target and to inhibit its biological
actions. It emphasizes the characteristic that various chemical moieties might share a similar property
and so be characterized by the same feature. In MOE, an inbuilt module pharmacophore query creates a
set of query features from annotation points of the ligand, receptor and ligand complex, and receptor only.
These features explain the crucial atoms and groups, namely, hydrogen donors, hydrogen acceptors,
aromatic centers, R-groups, charged groups and bioisosteres. Therefore, in the current study, combined
complex-based or receptor-based pharmacophore modeling was used to identify salient features and
create a pharmacophore query to screen virtual compound libraries for novel PaLpxA inhibitors.
Thus, a 3D pharmacophoric features query of the UDP-GlcNAc pocket of PaLpxA was generated using
the least square (LS) program of the pharmacophore query editor of MOE. The query consisted of a set
of constraints on the location and type of pharmacophoric features. The force field parameters were
set up using the potential setup in the MOE as follows: The force field was set to amber10:EHT [28];
solvation was set to R-field and bonded, van der Waals, electrostatics and restrains were enabled.
Hydrogen and partial charges were adjusted. Subsequently, in the LigX panel, the receptor strength
was tethered to 5000 to keep the receptor rigid. This enabled 3D protonation and deleted the water
molecules farther than 4.5 Å from the receptor or ligand. Consequently, the pharmacophore query
was created by applying the following parameters: The scheme was set to EHT to define the set
of attributes that are used to construct the ligand annotation points. These annotation points were
represented in the form of different colors—green for hydrophobic, purple for hydrogen bond donor,
cyan for hydrogen bond acceptor and orange for aromatic. The pharmacophore query was validated
by performing the pharmacophoric features search and the query was refined by changing features
iteratively. For potential leads, pharmacophoric features were condensed with reference to the key
residues within the binding pocket for better binding and orientation of the leads. A virtual screening
(VS) campaign was used as an in silico sieve using the modified and validated pharmacophore model to
screen the refined NCI virtual compound library [29,30]. The lowest binding energy conformations for
each ligand were saved in a separate MOE database by using the conformation import methodology.
Thereafter, each compound conformer was filtered by the pharmacophore model based on satisfying the
marked pharmacophoric features to be considered as a virtual hit. Subsequently, the identified virtual
hits were plotted on the designed pharmacophore and allowed for docking studies against PaLpxA.
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2.4. Molecular Docking
Molecular docking was performed for the pharmacophoric hits using the docking module of
MOE [31]. Hydrogens were added to the protein and subjected to protonation 3D. Partial charges were
added using the method of AMBER99 and energy was minimized using the following parameters
and methods. The gradient was set to 0.00001, and the MMFF94x force field was used with an enable
cut-off value set from 8 to 10; solvation was set to distance mode; dielectric was set to 1; exterior was
set to 8; and partial charges were fixed for required calculations. After minimization, the stabilized
protein molecule was used for further docking analysis. The docking site was set to the ligand atoms
within the crystal structure of PaLpxA. The descriptor filter was specified to satisfy the Lipinski rule of
five. The docking parameters were set as follows: The placement methodology was set to triangle
matcher to calculate initial poses and scores. The rescoring methodology was set to the London dG
function that ranks the docked poses. The maximum number of poses retained the 30 lowest docking
poses and removed the duplicates. The RMSD was calculated within 2 Å between the docked pose
and the crystal pose and considered as reliable docking for reproducibility. After docking, the best
lead molecules were identified based on the maximum docking score, and binding angles and bond
lengths were visually inspected using LigPlot and PyMOL.
2.5. Born Interaction Energies and Binding Affinities
Born-volume integral (GB/VI) implicit solvent methods were implemented in MOE to determine
the binding affinities of lead molecules [32]. Van Der Waals, Coulomb electrostatic interactions,
and implicit solvent interactions were termed the Born interaction energy, which determined
non-bonded interactions between the ligands and the protein. During the binding affinity assessment,
the draining energies, and solvent molecules of the ligand and the protein were ignored. The London
scoring method was represented in kcal/mol units for the binding affinity calculations. The binding
pocket residues and ligands were kept flexible, whereas the binding pocket was kept rigid to tether
restraints and discourage gross movements. Energy minimization for the protein–ligand complex was
employed, and the binding affinity was calculated.
2.6. Protein–Peptide Docking
Protein–protein docking was accomplished using the HDOCK server [33]. The hybrid docking
protocol uses a fast Fourier transform (FFT) scoring method by this server [34]. PaLpxA, E. coli
LpxA, peptide920 and RJPXD33, when subjected to docking, showed 100 binding modes with binding
energies. Of these, the top 10 ranked models were selected and manually inspected to ascertain the
proper binding conformation overlaid with reference crystals structures.
2.7. Bioavailability
Molecular properties, the Lipinski rule of five (molecular weight < 500, H-bond acceptor
< 10, H-bond donor < 5, and cLogP < 5), drug likeness, and toxicity properties (mutagenic,
tumorigenic, irritant and reproductive effects) were predicted using ADME (absorption, distribution,
metabolism and excretion) properties and assessed using the Swiss ADME (Lausanne, Switzerland)
and FAF-Drugs3 servers (Paris, France) [35,36].3. Results and Discussion
3. Results and Discussion
3.1. PaLpxA-Substrate Analysis
Biologically relevant functional homotrimer (monomer A, B and C) PaLpxA crystal structures
with the apo form, complexed with respective substrate and product, UDP-GlcNAc and
UDP-3-(R-3-hudroxydecanoyl)-GlcNAc, were resolved at 1.8 Å and were available in the PDB.
PaLpxA monomers A, B and C were identical, with some structural distinction within the loop region
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L1 and L2. PaLpxA monomer consisted of two discrete domains, the N-terminal β-strand domain and
C-terminal α-helical domain. The catalytic site lay between the protein–protein interface where the
C6 and C9 coils meet from adjacent monomers A and B. In the PaLpxA-substrate complex, the binding
position of UDP-GlcNAc was placed at the monomer A–monomer B interface, where UDP was situated
at monomer A, namely the UDP pocket, and GlcNAc was pinpointed at another monomer B in
the GlcNAc pocket; the diphosphate group acted as a connecting bridge (Figure 1a). UDP-GlcNAc
formed key contacts with active pocket residues, and the uracil moiety formed critical interactions,
such as O atom hydrogen bonds with Arg201, N atom hydrogen bonds with Asn194, and a Pi–Pi
interaction between the uracil ring and aromatic ring of Phe166 from monomer A. In addition, some
van der Waals forces resulted from the Ile148 and Glu196 towards the uracil ring. The 3OH of the
ribose sugar displayed an interaction with His156 of monomer B. The diphosphate group conferred
strong interactions with both monomers A and B, with Arg200 from monomer A forming two strong
hydrogen bonds with the O atom of the α-phosphate, and in turn, the O atom of the α-phosphate
hydrogen bonded with Gln157 from monomer B and the O atom of the β-phosphate. GlcNAc solely
formed contact with key residues of the GlcNAc pocket of monomer B. The acetyl group was located
on the second position and hydrogen bonded with the backbone of Leu71 by donating an electron.
The 3OH formed a strong polar bond with the catalytic base Nε2 of His121, allowing this residue
to perform a nucleophilic attack by deprotonating the 3OH. The 4OH also conferred a weaker polar
bond with the Nε2 of His121, and the 6OH formed two strong polar bonds with Lys72 and His140.
Furthermore, the crystal structures of LpxA-substrate complex from two orthologues, E. coli and B.
fragilis, were resolved and these were subjected to overlaying with the binding pose of UDP-GlcNAc of
PaLpxA. Noteworthy, significant marked variation was perceived with the orientation of the uridine
ring in both E. coli LpxA and PaLpxA (Figure 1b). The uridine ring, sugar and α-phosphate moieties
were flipped away in the pocket, with no perturbations in the GlcNAc position in E. coli LpxA. The UDP
moiety was unable to form a Pi–Pi interaction, due to the absence of a Phe residue, and formed a polar
interaction with His156 by flipping. Moreover, PaLpxA UDP-GlcNAc showed an identical binding
position with B. fragilis (Figure 1c). Owing to the variation in substrate orientation, the pocket residues
played an important role in the specificity and position of the substrate across orthologs.
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Figure 1. (a) PaLpxA consists of a homotrimer and each monomer is labeled with different color, 
UDP-GlcNAc is positioned within the diversified active site that is marked with a red circle between 
monomer A and B. LpxA is shown in the cartoon, whereas UDP-GlcNAc is shown in space-filling 
model. 3D binding interaction of UDP-GlcNAc (magenta) with key residues of PaLpxA pocket (light 
salmon for monomer A and dark salmon for monomer B). (b) Overlay of UDP-GlcNAc (magenta) 
within the diversified pocket of PaLpxA with UDP-GlcNAc (yellow) within the diversified pockets of 
E. coli LpxA dimer (dark brown for monomer A and light brown for monomer B) and (c). UDP-
GlcNAc (yellow) of B. fragilis LpxA dimer (light magenta for monomer A and dark magenta for 
monomer B). Hydrogen bonds are represented as dashed lines in cyan and green colors. Binding 
interactions are shown in blue and green colors. 
3.2. LpxA Pocket Analysis among Orthologs 
Protein–ligand interactions are a fundamental phenomenon in all biological mechanisms; 
however, these binding interactions are certainly specific due to the distinct pocket and ligand 
properties. Exclusively, the binding pocket, shape, and residue physico-chemical properties 
determine the nature of the pocket and distinguish from orthologs. Accordingly, binding pocket 
analysis and comparison can shed light on selectivity and binding properties of the ligand, and most 
importantly, resolve the molecular mechanism between the protein and the ligand in biological 
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Figure 1. (a) PaLpxA consists of a homotrimer and each monomer is labeled with different color,
UDP-GlcNAc is positioned within the diversified active site that is marked with a red circle between
monomer A and B. LpxA is sho n in the cartoon, hereas P-GlcNAc is shown in space-filling
model. 3D binding interaction of UDP-GlcNAc (magenta) with key residues of PaLpxA pocket (light
salmon for monomer A and dark salmon for monomer B). (b) Overlay of UDP-GlcNAc (magenta)
within the diversified pocket of PaLpxA with UDP-GlcNAc (yellow) within the diversified pockets of
E. coli Lpx dimer (dark brown for monomer A and light brown for mono er B) and (c). UDP-GlcNAc
(yellow) of B. fragilis LpxA dimer (light magenta for monomer A and dark magenta for onomer B).
Hydrogen bonds are represented as dashed lines in cyan and green colors. Binding interactions are
shown in blue and green colors.
3.2. LpxA Pocket Analysis among Orthologs
Protein–ligand interactions are a fundamental phenomenon in all biological mechanisms; however,
these binding interactions are certainly specific due to the distinct pocket and ligand properties.
Exclusively, the binding pocket, shape, and residue physico-chemical properties determine the nature
of the pocket and distinguish from orthologs. Accordingly, binding pocket analysis and comparison
can shed light on selectivity and binding properties of the ligand, and most importantly, resolve
the molecular mechanism between the protein and the ligand in biological systems. In this study,
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the PaLpxA structure was superimposed on LpxA orthologs from different bacterial pathogens to
determine differences in the key residues and shape of the pockets. The RMSD was calculated
between PaLpxA and different LpxA orthologs, and superimposition of PaLpxA revealed no significant
structural deviations, showing 0.516 Å for A. baumannii, 0.628 Å for E. coli, 0.628 Å for B. thailandensis,
0.638 Å for H. pylori and 0.803 Å for L. interrogans.
Furthermore, an assessment of the UDP-GlcNAc binding pocket revealed significant differences
in the critical residue composition at both the uridine and GlcNAc binding sites, as shown in Table 1.
The notable change at the uridine binding site of PaLpxA was that Phe166 was substituted for Met
between orthologues, and a structural shift was noticed with the key residue, Arg202, from A. baumannii
(Figure 2f). In the case of the GlcNAc pocket, the most prominent difference was that Tyr158 in PaLpxA
mutated with Phe162, Phe161, Phe158, and Phe157 residues in A. baumannii, E. coli, H. pylori and L.
interrogans, and Met72 and Phe72 were mutated in B. thailandensis and L. interrogans instead of Lys72.
B. thailandensis had a smaller cavity with variations in the flexible loop region (L1) that consisted of
Gln70 and Met72, instead of Lys72 and Leu71. H. pylori showed an outward conformation of Lys72 at
the L2 loop region. Conversely, the catalytic His residue and pocket histidine residues were found to
be highly conserved with slight conformational changes, excepting Tyr158. Significant variations were
also observed in the flexible loop region.
Table 1. Crucial residues in the diversified LpxA UDP-GlcNAc binding pocket, root mean square
deviation (RMSD) and pocket size from different orthologues.
Organism PDB ID
Monomer A Monomer B
RMSD (Å) Pocket Size (Å)UDP Pocket GlcNAc Pocket
P. aeruginosa 5DEM
Arg200, Arg201, Gly197
Glu196, Asn194, Phe166,
Ile148, Ile130, Leu112,
Met114
Asp70, Leu71, Lys72,
Ala138, Gly139, His121,
His140, His156, Gln157,
Tyr158
213
E. coli 2JF3
Arg204, Arg205, Glu201
Asn198, Met170, Ile152
Ile134, Leu116, Met118
Gln73, Asp74, Leu75,
Lys76, His125, Gly143,
His144, Gln161, Phe162
0.6 156
B. fragilis 4R37
Arg197, Arg198, Gly194,
Ile193, Asn191, Ile199,
Met163, Ile145, Ile127
Met111
Gln167, Asp68, Leu69,
Lys70, His118, Gly136,
Glu137, His153,
Gln154,
Phe155
0.8 123
H. pylori IJ2Z
Arg197, His196, Asn194
Thr182, Met166, Asn148,
Met130
Asp70, Leu71, Lys72,
His121, Gly139, His140,
Gln157, Phe158
0.6 208
L. interrogans 3HSQ Arg199, Val195, Gly196,Asn193, Met163, Ile129
Gln168, Asp69, Leu70„
Gly71, His120, His130,
Gly138, His155,
Gln156,
Phe157
0.8 205
A. baumannii 4E6Q
Asn197, Met185, Met169,
Ile151, Ile133, Leu115,
Met117
Gln172, Asp73, Leu74,
Lys75, His124, Gly142,
His143, His159, Gln160,
Phe161
0.5 170
B.
thailandensis 4EQY
Arg202, Gly198, Asn195,
Ile183, Met167, Ile149,
Val131, Met115
Gln70, Asp71, Met72,
His122, Gly140, His141,
His157, Gln158, Tyr159
0.6 145
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PaLpxA with six different bacterial LpxAs (b-g) to design marked inhibitors. (a) The 
binding orientation of UDP-GlcNAc within the bifurcated PaLpxA active pocket, with 
regions highlighted as a square region for UDP binding, a circle for GlcNAc binding and a 
rectangular region for product binding. LpxAs are depicted as cartoons and colored with 
different orthologues, essential pocket residues are shown as classical sticks and colored 
with elements. Overlays of PaLpxA (light salmon for monomer A and dark salmon for
monomer B) with (b) E. coli dimer (dark brown for monomer A and light brown for 
monomer B), (c) B. fragilis dimer (light magenta for monomer A and dark magenta for 
monomer B), (d) H. pylori dimer (light blue for monomer A and dark blue for monomer B), 
(e) L. interrogans dimer (light green for monomer A and dark green for monomer B), (f) A. 
baumannii (light yellow for monomer A and dark yellow for monomer B), and (g) B. 
thailandensis (light brown for monomer A and dark brown for monomer B). 
Figure 2. The structural orientation of UDP-GlcNAc binding cavity and superimposition of PaLpxA
with six different bacterial LpxAs (b-g) to design marked inhibitors. (a) The binding orientation of
UDP-GlcNAc within the bifurcated PaLpxA active pocket, with regions highlighted as a square region
for UDP binding, a circle for GlcNAc binding and a rectangular region for product binding. LpxAs are
depicted as cartoons and colored with different orthologues, essential pocket residues are shown as
classical sticks and colored with elements. Overlays of PaLpxA (light salmon for monomer A and
dark salmon for monomer B) with (b) E. coli dimer (dark brown for monomer A and light brown for
monomer B), (c) B. fragilis dimer (light magenta for monomer A and dark magenta for monomer B),
(d) H. pylori dimer (light blue for monomer A and dark blue for monomer B), (e) L. interrogans dimer
(light green for monomer A and dark green for monomer B), (f) A. baumannii (light yellow for monomer
A and dark yellow for monomer B), and (g) B. thailandensis (light brown for monomer A and dark
brown for monomer B).
Biomolecules 2020, 10, 266 9 of 23
In addition, the binding pocket shape was an essential feature that determined the appropriate
compounds with preferred biological targets. Several reports reinforced the molecular shape, which
plays a crucial role in the biological activity. Volumetric binding cavity analysis was performed and
is depicted in Figure 3. Pocket analysis exemplified different molecular pocket shapes with various
volume sizes and residue compositions within the LpxA adjacent monomers; these are represented
in the supplementary Table S1. The percentage of identity of the pocket residues between LpxA
orthologues compared with PaLpxA that enlighten B. fragilis showed the highest identity of 58%, while
E. coli and B. thailandensis showed 37%, L. interrogans showed 31%, and H. pylori and A. baumannii
showed 28% and 18%, respectively (Supplementary Table S2). Moreover, volumetric binding for P.
aeruginosa, H. pylori and L. interrogans showed the largest pocket surfaces with volume sizes of 224 Å,
209 Å, and 205 Å, respectively, while B. fragilis and B. thailandensis showed smaller pocket surfaces with
volumes of 123 Å and 145 Å, respectively. E. coli and A. baumannii showed the most similar pocket
surface volumes of 156 Å and 151 Å, respectively. The tendency of ligand binding residues in the
pocket revealed 5.1 for P. aeruginosa, 3.7 for H. pylori and 5.2 for L. interrogans, 3.2 for B. fragilis, 4.2 for B.
thailandensis, 3.9 for E. coli and 3.6 for A. baumannii. Intriguingly, the highest numbers of hydrophobic
contact atoms, such as 52 and 53, were found in P. aeruginosa and L. interrogans, H. pylori had 44 atoms,
and E. coli and B. fragilis had 36 and 32 atoms, respectively, whereas A. baumannii and B. thailandensis
had fewer numbers of hydrophobic atoms, with 22 and 18, respectively. In addition, 113, 106 and
105 side chain atoms were implicated in the ligand-binding pocket from P. aeruginosa, H. pylori and L.
interrogans, respectively. Different side chain atoms were involved in the pockets, such as 76 atoms in
E. coli, 69 atoms in B. fragilis, 61 atoms in A. baumannii and 60 atoms in B. thailandensis. The study of
shape and unique features of the pocket has gained importance in molecular pharmacology and the
aforementioned results might be helpful in the design of specific LpxA inhibitors.
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3.3. PaLpxA-Peptide Docking  
In the PaLpxA-UDP-3-O-(R-3-hydroxydecanoyl)-GlcNAc product complex, the acyl chain 
was linked with the 3O of GlcNAc and extended towards the hydrophobic acyl chain binding cavity 
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residues: Val132, Asn133, Gly151, Tyr152 and Met169 from monomer A; and Ala136 and Leu154 from 
monomer B. Fascinatingly, functional aspects of product formation from previous reports showed 
the acylated product length could be restricted among orthologs in the hydrophobic tunnel, the so-
called hydrocarbon ruler that designates specific residues that assess the suitable acylated chains, or 
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Figure 3. LpxA-UDP-GlcNAc binding cavity volume and shape analysis. The substrate-binding cavity
is enveloped with a smooth surface between adjacent monomers A and B. The grey color represents the
hydrophobic region and red color represents the hydrophilic region in different orthologues such as
(a) P. aeruginosa LpxA dimer (light salmon for monomer A and dark salmon for monomer B), (b) E. coli
LpxA dimer (dark brown for monomer A and light brown for monomer B), (c) B. fragilis LpxA dimer
(light magenta for monomer A and dark magenta for monomer B), (d) H. pylori LpxA dimer (light blue
for monomer A and dark blue for monomer B), (e) L. interrogans LpxA dimer (light green for monomer
A and dark green for monomer B), (f) A. baumannii LpxA dimer (light yellow for monomer A and dark
yellow for monomer B), and (g) B. thailandensis LpxA dimer (light brown for monomer A and dark
brown for monomer B).
3.3. PaLpxA-Peptide Docking
In the PaLpxA-UDP-3-O-(R-3-hydroxydecanoyl)-GlcNAc product complex, the acyl chain was
linked with the 3O of GlcNAc and extended towards the hydrophobic acyl chain binding cavity
(Figure 4a), wherein the acyl chain formed polar interactions by donating electrons to the side chain of
Met114 of monomer A and backbone of Ala138, and accepting an electron from His118 of monomer
B. Apart from this, numerous hydrophobic contacts were also observed with pocket surrounding
residues: Val132, Asn133, Gly151, Tyr152 and Met169 from monomer A; and Ala136 and Leu154 from
monomer B. Fascinatingly, functional aspects of product formation from previous reports showed the
acylated product length could be restricted among orthologs in the hydrophobic tunnel, the so-called
hydrocarbon ruler that designates specific residues that assess the suitable acylated chains, or else
it would not permit binding due to several deficient molecular interactions. For instance, E. coli has
residue His191 to act as a hydrocarbon ruler that allows only a 14C hydrocarbon chain, whereas L.
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interrogans has a Lys171 residue to allow a 12C hydrocarbon chain and P. aeruginosa has a Met169 that
permits a 10C hydrocarbon chain. Stabilization of the transition state during acylation of UDP-GlcNAc
occurred through a backbone amide group of a conserved Gly residue that acted as the oxyanion hole.
Previous studies reported several competitive peptide inhibitors that target the acyl binding
pocket of LpxA from E. coli. Williams et al. resolved the crystal structure of LpxA (1.8 Å) with
the pepide920 peptide inhibitor (WMLDPLAGKWSR), and Jenkins et al. determined the crystal
structure of LpxA (1.9 Å) in complex with the RJPXD33 (TNLYML) peptide inhibitor from E. coli
at different resolutions [16–18]. These antimicrobial peptide inhibitors selectively compete with an
acyl-ACP substrate and potentially inhibit E. coli LpxD and LpxA acyltransferases. However, in this
study we conducted docking experiments with these peptides for PaLpxA using the HDOCK server,
the results of which are presented in Table 2. Intriguingly, docking results showed peptide920 had
the highest binding energy of –263 kcal/mol, which was higher than RJPXD33 (–177 kcal/mol),
for PaLpxA, which was bound at the UDP-GlcNAc binding pocket. In the PaLpaA-Peptide920 complex,
Peptide920 showed a β-hairpin folded conformation in the bifurcated active pocket, and N and C
terminals exposed towards the solvent with the hairpin protruding into the pocket, as observed in the
E. coli LpxA-peptide920 complex (Figure 4b). Peptide920 formed crucial interactions with substrate
binding residues, N-terminal Met5 bonded with the uracil-binding residue Asn194, and Leu6 and
Asp7 bonded with α-phosphate-binding residue Arg200 from monomer A. The hairpin loop consisted
of four residues among Ile9 and Gly11 bonds, with Lys72 from monomer A and C-terminal
Trp13 displaying two bonds, such as one polar bond with His156 from monomer B and a pi–pi
bond with Phe166 from monomer A.
Table 2. Binding interaction, distance and binding energy of peptide inhibitors with active site residues
of PaLpxA.
Peptide Inhibitor
Binding
Interactions
Peptide
Protein Distance (Å)
Binding Energy
(Kcal/mol)
Peptide920
Trp13-----------Phe166
Met5-----------Asn194
Leu6-----------Arg200
Asp7-----------Arg200
monomer A 2.9
3.6
3.0
2.9
3.7
2.3
3.8
−263
Ileu9-------------Lys72
Gly11-------------Lys72
Trp13------------His156
monomer B
RJPXD33
Leu6------------Phe166
Met5-----------Met169 monomer A
2.9
2.4
3.5
3.5
3.4
3.3
−177Thr1------------His121
Thr1------------His118
Thr1------------Gln157
Asn2-------------Asp70
monomer B
While the RJPXD33 peptide inhibitor tethered vertically up at the bifurcated pocket of PaLpxA,
the Thr1, Asn2, Leu3 and Met5 residues of the peptide occupied the GlcNAc binding pocket and
hydrophobic cleft of monomer B. Thr1 formed hydrogen bonds with catalytic residues His121,
Gln157 and His118 of monomer B. Asn2 displayed one polar bond with Asp70, and Met5 directly
interacted via an S–S bond with Met169, the acyl chain ruler. Leu6 and Tyr4 were positioned at the
uracil binding site of monomer A. Leu6 interacted with Phe166 through a pi–pi interaction (Figure 4c).
However, peptide inhibitors lack the peptide delivery system into the bacterial cytoplasm, and so
it is not an optimistic approach for targeting cytoplasmic proteins. However, the peptide binding
analysis can guide us to design safer and greater bioavailability inhibitors. An alternative approach is
the design of small molecules that target the LPS biosynthesis pathway.
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3.4. Pharmacophore-Based Virtual Screening
Designing effective and specific drugs depends mainly on the volume and shape of the target
protein cavity combined with the physicochemical characteristics that are implicated in the binding and
position of the ligand. Pharmacophore modeling is a persuasive process to determine novel hits and
lead molecules. In this study, a pharmacophore model was developed using a complex-based approach.
In this scenario, physicochemical characteristics, spatial arrangements, and the shape and volume
of the binding cavity were considered. A receptor–ligand complex-based pharmacophore model
was accomplished. A pharmacophore model constructed with fourteen pharmacophoric features,
namely, three hydrogen bonding donors, nine hydrogen bond acceptors and two aromatic centers
(Figure 5a,b). However, as aforementioned, the substrate and product shared pharmacophoric groups
with binding pocket residues of PaLpxA. Three residues in the structure—Asn194, Phe166 and Arg200—
in monomer A formed a hydrogen bond with the uracil moiety. Gln157 and His121 of monomer B
formed bonds with GlcNAc and performed catalysis. Five pharmacophoric features—F3 (Donor),
F4 (aromatic), F6 (acceptor), F12 (acceptor), and F9 (acceptor)—were identified as essential features
that display critical interactions with substrate binding residues and the pharmacophore model was
generated (Figure 5c). The developed 3D pharmacophore model provided an important functionality
that contributed to the selection of selective inhibitors and, therefore, was used as a filter in the virtual
screening process. The NCI database contains 265,242 heterogeneous compounds and was subjected
to virtual screening against our developed pharmacophore model that deliberated 1718 virtual hits,
which were superimposed with a query compound. Accordingly, these screened hits were docked and
the top ranked lead molecules were identified, based on the best binding energies with corresponding
binding conformation within the pocket, and overlaid with substrate to ensure conformation of the
leads (Figure 5d).
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sal on for monomer A and dark salmon for monomer B). (b) 3D pharmacophore annotation of
UDP-GlcNAc with projections pinpoint the receptor pharmacophores. (c) Key pharmacophoric features
with distance constraints within the pocket. (d) Superimposition of top-ranked pharmacophoric hits
with the binding conformation of UDP-GlcNAc. When overlaid with the binding conformation of
UDP-GlcNAc (balls and sticks, magenta), the virtual hits are rendered with sticks in yellow. (Don&Acc:
Hydrogen bond donor/acceptor, Aro: Aromatic center, Don: Hydrogen bond donor, Acc: Hydrogen
bond acceptor).
3.5. Molecular Docking
To evaluate the lead molecules, all the pharmacophoric hits were docked in the GlcNAc binding
pocket of LpxA by using the docking module of MOE. The docked conformation of ligands approving
to the highest docking score with a low RMSD value was selected as the most efficient binding
orientation. To validate the docking protocol, UDP-GlcNAc was redocked into the binding pocket,
and the best binding pose, with a binding energy of –6.9 kcal/mol, was superimposed with crystal
ligand that revealed a similar conformation with RMSD of 1.2 Å, indicating that the docking protocol
was reliable (Figure S2a). The binding energy denotes the sum of the total internal energy, torsional
free energy and intermolecular energy subtracted from the unbound energy system. The lowest free
energy binding conformation specifies stable protein and ligand complex system anddetermine highest
affinity among them. Docking results of virtual hits showed the binding energies ranged from –6.5 to
–10.5 kcal/mol. A total of 137 top ranked ligands were selected based on the binding energies from
–10.5 to –7.4 kcal/mol, with RMSD tolerance of 2.0 Å for further affinity evaluations.
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3.6. Born Interaction Energies and Binding Affinities
The generalized Born/volume integral (GB/VI), Born interaction energies and binding affinities
were calculated using MOE to uncover the binding energy, binding affinity and interactions of lead
molecules. The energy minimization employed for each complex and binding affinity (Kcal/mol) was
measured. By analyzing the binding affinity and binding energy, 10 molecules could unambiguously
be chosen from the top rank docked compounds (Table 3). Therefore, the protein–ligand interactions
were analyzed to reveal significant implicated atoms with tether restraint through 2D assessments that
exclude the false positives due to assumptions and deficiencies in the docking protocol and the scoring
methods (Figure 6) [25,37].
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Compound 75326 formed six bonds with key residues of the pocket. A sulfonyl group bonded
with Asn194, one hydrogen-arene contact occurred between Ile130 and the nitrophenyl moiety,
and hydrophobic interactions were observed between the aromatic ring and the Ala118 backbone
of monomer A. Another sulfonyl group formed three polar bonds with Lys72, Tyr158 and
Gln157 of monomer B. Compound 162530 exhibited seven contacts with key residues, but sulfonyl
moieties were able to interact with pocket residues from two monomers A and B. One sulfonyl
group bonded with the uridine-binding residues Asn194, Arg200 and Arg201 from monomer
A, while two sulfonyl groups bonded with GlcNAc binding residues of Gln157 and Lys72 from
monomer B. Compound 381868 showed three binding interactions, with Arg200, Gln157 and Met114.
Compound 68858 displayed four bonds, such as hydroxy bonds, with Arg191 and hydroxy–ethoxy
moiety showed one hydrogen–arene contact with Phe166 of monomer A. However, phosphoryl and
ethoxy groups formed two bonds with Gln157 and His156 of monomer B. Compound 372529 exhibited
five bonds, and the carboxylic group of butanoic acid showed one bond specifically implicated
with product binding residue Met169 and Gln157. A sulfonamide group bonded with Phe66 and
Ser150 of monomer A and one butanoic acid formed a bond with the His118 residue of monomer B.
Compound 293892 showed eight bonds, with dihydropurine-2-6-dione showing two hydrogen–arene
interactions with Phe166 and Gln196, hydroxy moiety bonds with Ser150 and Gly151, and a phenyl
ring displaying an arene–hydrogen bond with Gly151 and Met169, and one polar bond with Met114.
Compound 353465 displayed critical interactions with both monomers A and B, tetrahexoxa displayed
two polar bonds via an oxygen atom with monomer B residues, such as Lys72 and Gln7, whereas
the O atom of the tetraon showed two polar bonds with monomer A residues Asn194 and Arg201.
Compound 366068 displayed three bonds, the O atom of azone bonding to Asn194 and Arg201 of
monomer A, and the tricyclo tetracosane tetron forming two bonds with the GlcNAc binding pocket
residues Lys72 and Gln157. Compound 321495 showed two bonds: an SH group of carbamimidothioic
acid formed one bond with Arg200 of monomer A, and the S atom of the phenylmethanethiol
group bonded with Asp70 from monomer B. Compound 7529 displayed five bonds, such as the 2, 5,
dihydrofuran-2-one group forming two bonds with the uridine-binding residues Asn194 and Arg200 of
monomer A, the 5OH of methyloxan forming key interactions with Asp70 and Lys71, and the 4OH
and O groups of methyloxan bonding with Lys72 and Gln157 of monomer B. Thus, the assays of
pharmacophore mapping, docking score, binding energy, binding affinity, binding pose and interactions
with key residues of the binding pocket can lead to structurally diverse scaffolds that act as selective
potent LpxA inhibitors (Figure 7). The molecular interaction analysis of these lead molecules can
inhibit the UDP-GlcNAc pocket by competing with substrate. Subsequently, these compounds were
evaluated for physicochemical, pharmacokinetic and ADME properties. The failure of drug accessing
raises safety related concerns and is even more significant in the drug discovery pipeline, and actsas
a guide to the medicinal chemist in creating drug design programs. And so, we utilized in silico
approaches for identification of the ligand toxicophores and ADME properties.
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Figure 7. Top-ranked inhibitors (magenta) are rendered in the UDP-GlcNAc pocket and key residues
are shown as sticks, colored by atoms and labeled. PaLpxA dimer (light salmon for monomer A and
dark salmon for monomer B) is represented as a cartoon. Binding interactions are displayed by red
dotted lines.
Table 3. Binding interaction, bond distances, bond angles, binding energies and binding affinities of
the leads with PaLpxA.
Lead
Molecules
Binding Interaction Atoms Involved in
Angle
Angle (∠) Distance
(Å)
Docking
Score (S)
Binding
Affinity (pKi)Protein Ligand
75326
Asn194----------O
Ile130---------arene
Ala138---------arene
Lys72---------S=O
Tyr158-------- S=O
OD2-OD1-H38
HE2-NE2-O27
HE2-NE2-O25
NE2-HE2-CN1
NE2-HE2-O26
26.5
49.2
40.4
24.4
40.6
3.4
3.2
3.3
3.6
3.9
−10.5 −6.7
162530
Asn194----------O=S
Arg200---------O=S
Arg201---------O-S
Arg201- O=S
Lys72-- O=S
Lys72---------O-S
NZ-HZ-O28
NE2-HE-O29
N1-N-C
O27-N-C
HE2-NE2-O25
NE2-HE2-CN1
64.6
53.6
22.9
95.0
49.2
79.8
3.0
3.7
3.1
3.1
4.3
3.3
−10.1 −6.9
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Table 3. Cont.
Lead
Molecules
Binding Interaction Atoms Involved in
Angle
Angle (∠) Distance
(Å)
Docking
Score (S)
Binding
Affinity (pKi)Protein Ligand
381868
Arg200---------O
Gln157---------O
Met114--------OH
NZ-HZ-O31
NE2-HE-O32
N-N-C
30.5
35.4
21.8
3.1
3.0
4.0
−7.4 −7.9
68858
Phe166---------C
Gln157---------O-C
Gln157---------O-P
His156---------O-P
Arg191---------OH
NE2-HE-O27
ND1-CE1-H42
N-N-O
N-O-C
ND1-CE1-H42
69.2
84.1
29.6
19.9
80.3
2.9
3.9
3.2
3.5
−7.4 −7.1
372529
Phe166---------O=S
Ser150---------HN
Gln157---------C
His118---------O
Met169---------OH
NZ-HZ-O27
NE2-HE-N3
NE-HE-N3
NZ-HZ-O31
NE2-CD2-O28
33.8
35.3
90.8
60.7
84.1
3.1
3.3
3.9
3.1
4.0
−7.6 −7.6
293892
Phe166---------HN
Ser150---------OH
Glu196---------arene
Gly151---------arene
Gly151---------OH
Met169---------arene
Gly151---------C
CG-OD2-H46
NZ-HZ-O31
O-O-N
O-N-C
O-N-C
OH-HH-O27
O-N-C
54.5
4.6
60.7
45.8
97.7
76.9
35.3
4.6
4.3
4.5
3.0
3.1
3.3
3.9
−7.3 −7.3
353465
Asn194----------O=C
Arg201---------O=C
Lys72-----------O
Gln157---------O
F-N-C
F-N-C
C-C-O
N-O-C
22.2
86.8
76.9
76.7
3.5
3.3
4.0
4.9
−8.9 −6.7
366068
Asn194----------OH
Arg201---------OH
Lys72---------O
HE2-NE2-O25
NE2-HE2-CN1
NE-HE-N3
45.8
97.7
76.9
3.3
3.9
3.1
−8.6 −6.4
321495 Arg200---------SAsp72---------S
NE2-HE-O29
C-C-O
60.7
45.8
3.7
3.1 −8.5 −6.6
7529
Asn194----------O
Arg201---------O=C
Lys72---------O
Leu71---------OH
Gln157---------O
NZ-HZ-O28
N1-N-C
NE2-HE2-CN1
NZ-HZ-O31
OH-HH-O27
4.6
60.7
45.8
84.1
29.6
4.5
3.0
3.1
3.3
3.1
−8.5 −8.0
3.7. Bioavailability and ADME Properties
Bioavailability of the lead molecules plays a major role in drug discovery, and molecular properties,
pharmacodynamics, pharmacokinetics, the Lipinski rule, and toxicological properties are noteworthy
to distinguish drug accessibility. However, pharmacodynamic findings have uncovered leads that
have therapeutic potential by selectively targeting the active site of LpxA. The bioavailability for
the leads was evaluated with the Swiss ADME and FAF-Drugs server. The bioavailability radar
hat was generated which manifest promising drug likeness by using the Lipinski rule to predict
lipophilicity (–0.7 to +0.5), size (150 g/mol > 500 g), polarity (20–130A), solubility (<6), flexibility
(<9) and saturation (0.25–1) (Figure 8; Figure S3). The Lipinski rule of the leads computed that the
molecular weight was found to be less than 500. The cLogP or partition coefficient played a critical
role in the drug availability, and was determined to be less than five. Hydrogen bond acceptors were
computed to be less than ten (≤10) and hydrogen bond donors to be less than five (≤5). Water solubility
revealed that the absorption of drug molecules was projected to be soluble and moderately soluble.
In addition, predictions of skin permeability, gastrointestinal absorption and blood brain barrier (BBB)
permeability, as well as the interactions with different cytochrome p450 isoforms in drug elimination,
were documented. Drug likeness mainly dealt with the molecular features that were compatible
with absorption, distribution, metabolism and excretion in the body. Further, oral drug analysis was
evaluated by estimating the Lipinski rule, Ghose (Amgen), Veber (GSK), Egan (Pharmacia) and Muegge
(Bayer), which unambiguously determined it to be an oral drug (Table S2). Toxicity evaluations via
mutagenic, tumorigenic, irritant and reproductive effects were determined to exert no adverse effect.
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A drug score was calculated based on the above four risk factors to identify all compounds displaying
best drug score. Hence, these drug candidates might be promoted as promising antibacterial agents for
the efficacious management of bacterial infections.
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Figure 8. Drug likeness of leads was predicted using bioavailability radar. Pink depicts the optimal
range of each property (Lipo: Lipophilicity, Size: Molecular weight, POLAR: Total Polar Surface Area,
INSOLU: Insolubility, INSATU: Insaturation, FLEX: Flexibility).
4. Conclusions
P. aeruginosa is a perilous multidrug-resistant Gram-negative bacterium, which drastically reduces
the action of current drug potential through a variety of mechanisms and that often leads to therapeutic
failure. LPS biosynthesis is an important mechanism in bacteria, and LpxA is a validated essential
therapeutic target for design of potent antimicrobials against P. aeruginosa. In this study, crystal
structures of LpxA from different bacterial pathogens were extracted and substrate binding cavity size,
residue composition, hydrophilic and hydrophobic characteristics, and substrate binding position
differences were analyzed. This information enabled us to rationally identify specific chemical
groups to improve existing inhibitors and design new classes of selective inhibitors. We identified
Biomolecules 2020, 10, 266 21 of 23
unique residue compositions at the active site, pocket volume and characteristic pocket of PaLpxA.
Further, we created pharmacophore models using a complex-based approach and utilized crucial
pharmacophoric regions implicated in key substrate-binding residues as a pharmacophore query to
screen a heterogenous dataset to validate diverse scaffolds with potential pharmacophoric features.
Subsequently, a combination of docking and Born integral volume energy studies was applied to
determine binding energy and binding affinities of virtual hits to reveal 14 molecules as potential leads
for PaLpxA inhibition. For these optimized potential leads, bioavailability properties were elucidated,
revealing conspicuous remedial properties. However, to ensure their pharmacological properties, they
must be assessed in further clinical stages. This study opens new observations for the generation
of a rational drug discovery of LpxA antibacterial drugs with reference to clinical management of
multidrug-resistant bacteria.
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